Comparison between low and high doses of radioactive iodine in the treatment of thyroid cancer

A randomized clinical trial for the evaluation of the efficacy of 30 mCi versus 100 mCi, 131I for ablation of residual thyroid tissue

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138706171100N2

Enrollment

341

Registered

2011-08-16

Start date

2005-06-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffrentiated Thyroid Cancer. Malignant neoplasm of thyroid gland

Interventions

Intervention 1: Low dose (30 mCi). Intervention 2: High dose (100 mCi) of I-131.

Treatment - Drugs

Low dose (30 mCi)

High dose (100 mCi) of I-131

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with differentiated thyroid carcinoma (DTC): without any history of ablation therapy; with no palpable mass in the neck; with no evidence of capsular; vascular or lymph node invasion. Exclusion criteria: Any area of I-131 uptake in post-treatment whole body scan; Failing to follow the patients.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Response to treatment with I-131. Timepoint: 6 Months. Method of measurement: Tg, AntiTg tests and whole body scan with I-131.	—

Secondary

Measure	Time frame
Disease recurrence. Timepoint: 6 and 12 months. Method of measurement: Lab measurements, sonography and clinical assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Babak Fallahi

Research Institute for Nuclear Medicine, Tehran University of Medical Sciences

bfallahi@sina.tums.ac.ir+98 21 8863 3333

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026